3rd December 2024 Watch: MPM BioImpact Founder and Managing Partner Ansbert Gadicke on the BioVenture Voices Podcast with Chris Garabedian
18th November 2024 MPM BioImpact-Founded Company, Syndax, Announces FDA Approval of Revuforj® (revumenib)
